<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616430</url>
  </required_header>
  <id_info>
    <org_study_id>ATOS-010</org_study_id>
    <nct_id>NCT04616430</nct_id>
  </id_info>
  <brief_title>Topical Endoxifen in Women</brief_title>
  <acronym>CREME</acronym>
  <official_title>Karma CREME-1: A Double-blind, Placebo-controlled, Three-armed, Pilot Study of the Effects, Safety and Tolerability of Topical Endoxifen in Women Within the Karma Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atossa Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Atossa Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Karma CREME-1 consisted of 90 participants from the Karma Cohort. The major focus of the&#xD;
      pilot trial was to estimate time to mammographic density change. The primary objective was to&#xD;
      determine the effect size of the breast density change between topical placebo and two doses&#xD;
      of topical endoxifen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2018</start_date>
  <completion_date type="Actual">September 4, 2019</completion_date>
  <primary_completion_date type="Actual">September 10, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mammographic Breast Density At Study Exit</measure>
    <time_frame>From baseline to study exit up to 6 months</time_frame>
    <description>Change, on an individual level, in mammographic breast density, measured at 6 months or when exiting from the study (baseline screening mammography)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Mammographic Breast Density</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical Placebo:Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Endoxifen 10mg/breast/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Endoxifen 20mg/breast/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical endoxifen</intervention_name>
    <description>topical solution</description>
    <arm_group_label>Topical Endoxifen 10mg/breast/day</arm_group_label>
    <arm_group_label>Topical Endoxifen 20mg/breast/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>topical</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant in the Karma Cohort&#xD;
&#xD;
          -  Attending the national mammography screening program, i.e., aged 40-74 and have&#xD;
             performed a screening mammogram maximum 3 months prior to study inclusion&#xD;
&#xD;
          -  Mammographic density ~4.5 % density (volumetric) measured by Volpara, at the screening&#xD;
             mammogram performed in connection to baseline (maximum 3 months prior to inclusion).&#xD;
             The threshold value of 4.5% corresponds to the clinical Bl-RADS score A&#xD;
&#xD;
          -  Postmenopausal, defined as no period of menstruation during last 12 months independent&#xD;
             of any hormonal treatment&#xD;
&#xD;
          -  Informed consent must be signed before any study specific assessments are performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any previous or current diagnosis of breast cancer (including carcinoma in situ).&#xD;
&#xD;
          -  Any previous diagnosis of cancer with the exception of non-melanoma skin cancer and in&#xD;
             situ cancer of the cervix.&#xD;
&#xD;
          -  A history of major surgery of the breast, e.g., reduction or enlargement, which might&#xD;
             affect density measurements.&#xD;
&#xD;
          -  Mammographic Bl-RADS malignancy code 3, or above, at baseline mammography, or at&#xD;
             mammography during time of treatment. Recall for additional examinations due to&#xD;
             technical problems with the mammogram is accepted.&#xD;
&#xD;
          -  Currently using estrogen and progesterone based hormone replacement therapy (oral or&#xD;
             patches). Local estrogen treatment is accepted (ex. Vagifem).&#xD;
&#xD;
          -  Non-medical approved drugs against hot-flashes including phytoestrogen.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>heatlhy post-menopausal women</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Hall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <state>Sodersjukhuset</state>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <results_first_submitted>May 3, 2021</results_first_submitted>
  <results_first_submitted_qc>May 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 18, 2021</results_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT04616430/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>Topical Placebo:Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil&#xD;
Placebo: topical</description>
        </group>
        <group group_id="P2">
          <title>Topical Endoxifen 10mg/Breast/Day</title>
          <description>10 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil&#xD;
Topical endoxifen: topical solution</description>
        </group>
        <group group_id="P3">
          <title>Topical Endoxifen 20mg/Breast/Day</title>
          <description>20 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil&#xD;
Topical endoxifen: topical solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>Topical Placebo:Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil&#xD;
Placebo: topical</description>
        </group>
        <group group_id="B2">
          <title>Topical Endoxifen 10mg/Breast/Day</title>
          <description>10 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil&#xD;
Topical endoxifen: topical solution</description>
        </group>
        <group group_id="B3">
          <title>Topical Endoxifen 20mg/Breast/Day</title>
          <description>20 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil&#xD;
Topical endoxifen: topical solution</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="30"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.9" spread="6.01"/>
                    <measurement group_id="B2" value="56.9" spread="7.97"/>
                    <measurement group_id="B3" value="57.7" spread="8.41"/>
                    <measurement group_id="B4" value="56.5" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="30"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="30"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="30"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.9" spread="2.77"/>
                    <measurement group_id="B2" value="25.6" spread="3.57"/>
                    <measurement group_id="B3" value="25.2" spread="3.08"/>
                    <measurement group_id="B4" value="25.2" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood pressure (systolic)</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="30"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117.5" spread="12.1"/>
                    <measurement group_id="B2" value="123.7" spread="8.45"/>
                    <measurement group_id="B3" value="120.4" spread="10.1"/>
                    <measurement group_id="B4" value="120.5" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="30"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.0" spread="7.33"/>
                    <measurement group_id="B2" value="69.8" spread="9.74"/>
                    <measurement group_id="B3" value="70.2" spread="9.31"/>
                    <measurement group_id="B4" value="69.7" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="30"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.6" spread="5.14"/>
                    <measurement group_id="B2" value="165.3" spread="6.38"/>
                    <measurement group_id="B3" value="167.0" spread="6.06"/>
                    <measurement group_id="B4" value="166.3" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mammographic Breast Density</title>
          <units>% Dense Tissue</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="30"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.6" spread="17.2"/>
                    <measurement group_id="B2" value="23.9" spread="12.9"/>
                    <measurement group_id="B3" value="26.2" spread="18"/>
                    <measurement group_id="B4" value="24.6" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood pressure (diastolic)</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="30"/>
                    <count group_id="B4" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.0" spread="7.13"/>
                    <measurement group_id="B2" value="79.7" spread="5.86"/>
                    <measurement group_id="B3" value="77.0" spread="7.13"/>
                    <measurement group_id="B4" value="77.4" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mammographic Breast Density At Study Exit</title>
        <description>Change, on an individual level, in mammographic breast density, measured at 6 months or when exiting from the study (baseline screening mammography)</description>
        <time_frame>From baseline to study exit up to 6 months</time_frame>
        <population>Due to dropouts, analysis could only be performed 1 time at study exit. Participants were encouraged to have a mammogram at study exit; not all did.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>Topical Placebo:Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil&#xD;
Placebo: topical</description>
          </group>
          <group group_id="O2">
            <title>Topical Endoxifen 10mg/Breast/Day</title>
            <description>10 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil&#xD;
Topical endoxifen: topical solution</description>
          </group>
          <group group_id="O3">
            <title>Topical Endoxifen 20mg/Breast/Day</title>
            <description>20 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil&#xD;
Topical endoxifen: topical solution</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mammographic Breast Density At Study Exit</title>
          <description>Change, on an individual level, in mammographic breast density, measured at 6 months or when exiting from the study (baseline screening mammography)</description>
          <population>Due to dropouts, analysis could only be performed 1 time at study exit. Participants were encouraged to have a mammogram at study exit; not all did.</population>
          <units>percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.85" spread="5.58"/>
                    <measurement group_id="O2" value="-2.14" spread="6.50"/>
                    <measurement group_id="O3" value="-3.75" spread="7.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>Topical Placebo:Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil&#xD;
Placebo: topical</description>
        </group>
        <group group_id="E2">
          <title>Topical Endoxifen 10mg/Breast/Day</title>
          <description>10 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil&#xD;
Topical endoxifen: topical solution</description>
        </group>
        <group group_id="E3">
          <title>Topical Endoxifen 20mg/Breast/Day</title>
          <description>20 mg/day topical (Z)-endoxifen; Transcutol™ (2-(2-Ethoxyethoxy)ethanol); isopropanol, Crodamol™ GTCC (a fully saturated emollient triester) and mineral oil&#xD;
Topical endoxifen: topical solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (24.0}</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Rapid heart rate or palpitations</sub_title>
                <counts group_id="E1" events="25" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Feel lightheaded (dizzy)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="30"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyesight changes</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Difficulty swallowing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Feel bloated</sub_title>
                <counts group_id="E1" events="24" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Burning feeling from breast tissue or breast skin</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Fragile mucous membranes</sub_title>
                <counts group_id="E1" events="39" subjects_affected="18" subjects_at_risk="30"/>
                <counts group_id="E2" events="22" subjects_affected="14" subjects_at_risk="30"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Irritation from the breast skin</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Itching from the breast skin</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="36" subjects_affected="21" subjects_at_risk="30"/>
                <counts group_id="E3" events="36" subjects_affected="22" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Lack of energy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain from breast tissue or breast skin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Redness on breast skin</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Swelling of arms or legs</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Deviating lab value</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="31" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Lack of appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle cramps (e.g. in legs)</sub_title>
                <counts group_id="E1" events="38" subjects_affected="18" subjects_at_risk="30"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain in joints</sub_title>
                <counts group_id="E1" events="34" subjects_affected="14" subjects_at_risk="30"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Difficulty concentrating</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Feeling drowsy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="31" subjects_affected="17" subjects_at_risk="30"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="30"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Numbness/tingling in the hands and feet</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Difficulty sleeping</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Feeling nervous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Feeling sad</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Irritable</sub_title>
                <counts group_id="E1" events="22" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="21" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sexual feeling decreased</sub_title>
                <counts group_id="E1" events="50" subjects_affected="23" subjects_at_risk="30"/>
                <counts group_id="E2" events="28" subjects_affected="19" subjects_at_risk="30"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Worry</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Problems with urination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast sensitivity/tenderness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dryness vaginal</sub_title>
                <counts group_id="E1" events="46" subjects_affected="22" subjects_at_risk="30"/>
                <counts group_id="E2" events="33" subjects_affected="22" subjects_at_risk="30"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Menopausal hot flushes</sub_title>
                <counts group_id="E1" events="48" subjects_affected="19" subjects_at_risk="30"/>
                <counts group_id="E2" events="22" subjects_affected="14" subjects_at_risk="30"/>
                <counts group_id="E3" events="17" subjects_affected="16" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="47" subjects_affected="21" subjects_at_risk="30"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Painful intercourse</sub_title>
                <counts group_id="E1" events="41" subjects_affected="19" subjects_at_risk="30"/>
                <counts group_id="E2" events="24" subjects_affected="16" subjects_at_risk="30"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vaginal bleeding or spotting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="25" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vaginal itching/irritation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hair loss</sub_title>
                <counts group_id="E1" events="19" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E2" events="14" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Rashes on breast skin</sub_title>
                <counts group_id="E1" events="24" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E2" events="35" subjects_affected="21" subjects_at_risk="30"/>
                <counts group_id="E3" events="43" subjects_affected="26" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Skin rashes</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E3" events="22" subjects_affected="17" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early discontinuation of subjects due to AEs related to skin reactions lead to small numbers of completed subjects and inability to analyze the primary endpoint as outlined in the protocol.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Steven Quay</name_or_title>
      <organization>Atossagenetics</organization>
      <phone>206.419.4873</phone>
      <email>steven.quay@atossainc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

